Jimme K Wiggers1, Bas Groot Koerkamp2, David van Klaveren3, Robert J Coelen4, C Yung Nio5, Peter J Allen6, Marc G Besselink4, Olivier R Busch4, Michael I D'Angelica6, Ronald P DeMatteo6, T Peter Kingham6, Thomas M van Gulik4, William R Jarnagin6. 1. Department of Surgery, Cancer Center Amsterdam, Amsterdam, The Netherlands; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. Electronic address: Jim.wiggers@gmail.com. 2. Department of Surgery, Erasmus Medical Center, Rotterdam, The Netherlands; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. 3. Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands. 4. Department of Surgery, Cancer Center Amsterdam, Amsterdam, The Netherlands. 5. Department of Radiology, Academic Medical Center, Amsterdam, The Netherlands. 6. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Abstract
BACKGROUND: Many patients with resectable perihilar cholangiocarcinoma (PHC) on imaging are diagnosed intraoperatively with occult metastatic or locally advanced disease, precluding a curative-intent resection. This study aimed to develop and validate a preoperative risk score. STUDY DESIGN: Patients with resectable PHC on imaging who underwent operations in 2 high-volume centers (US and Europe) between 2000 and 2015 were included. Multivariable logistic regression analysis was used to develop the risk score. Cross-validation was used to validate the score, alternating the 2 centers as "training" and "testing" datasets. RESULTS: Of 566 patients who underwent operations, 309 (55%) patients had a resection, and in 257 (45%) patients, a curative-intent resection was precluded due to distant metastasis (n = 151 [27%]) or locally advanced disease (n = 106 [19%]). Preoperative predictors included bilirubin >2 mg/dL, bile duct involvement on imaging, portal vein involvement on imaging (≥180 degrees), hepatic artery involvement on imaging (≥180 degrees), and suspicious lymph nodes on imaging. The new risk score (c-index 0.75 after cross-validation) provided significantly more accurate predictions than the Bismuth classification (c-index 0.62), Blumgart T-staging (c-index 0.67), and cTNM staging (c-index 0.68). The new risk score identified 4 risk groups for occult metastatic or locally advanced disease: low (14.7%), intermediate (29.5%), high (47.3%), and very high risk (81.3%). The preoperative score groups also predicted survival after operation, irrespective of intraoperative findings (p < 0.001). CONCLUSIONS: The validated risk score can predict occult distant metastatic or locally advanced PHC based on 5 preoperatively available factors. The score can be useful in preoperative shared decision making and selection of patients in neoadjuvant clinical trials.
BACKGROUND: Many patients with resectable perihilar cholangiocarcinoma (PHC) on imaging are diagnosed intraoperatively with occult metastatic or locally advanced disease, precluding a curative-intent resection. This study aimed to develop and validate a preoperative risk score. STUDY DESIGN:Patients with resectable PHC on imaging who underwent operations in 2 high-volume centers (US and Europe) between 2000 and 2015 were included. Multivariable logistic regression analysis was used to develop the risk score. Cross-validation was used to validate the score, alternating the 2 centers as "training" and "testing" datasets. RESULTS: Of 566 patients who underwent operations, 309 (55%) patients had a resection, and in 257 (45%) patients, a curative-intent resection was precluded due to distant metastasis (n = 151 [27%]) or locally advanced disease (n = 106 [19%]). Preoperative predictors included bilirubin >2 mg/dL, bile duct involvement on imaging, portal vein involvement on imaging (≥180 degrees), hepatic artery involvement on imaging (≥180 degrees), and suspicious lymph nodes on imaging. The new risk score (c-index 0.75 after cross-validation) provided significantly more accurate predictions than the Bismuth classification (c-index 0.62), Blumgart T-staging (c-index 0.67), and cTNM staging (c-index 0.68). The new risk score identified 4 risk groups for occult metastatic or locally advanced disease: low (14.7%), intermediate (29.5%), high (47.3%), and very high risk (81.3%). The preoperative score groups also predicted survival after operation, irrespective of intraoperative findings (p < 0.001). CONCLUSIONS: The validated risk score can predict occult distant metastatic or locally advanced PHC based on 5 preoperatively available factors. The score can be useful in preoperative shared decision making and selection of patients in neoadjuvant clinical trials.
Authors: W R Jarnagin; Y Fong; R P DeMatteo; M Gonen; E C Burke; J Bodniewicz BS; M Youssef BA; D Klimstra; L H Blumgart Journal: Ann Surg Date: 2001-10 Impact factor: 12.969
Authors: D Erdogan; J J Kloek; F J W ten Kate; E A J Rauws; O R C Busch; D J Gouma; T M van Gulik Journal: Br J Surg Date: 2008-06 Impact factor: 6.939
Authors: Michelle L Deoliveira; Richard D Schulick; Yuji Nimura; Charles Rosen; Gregory Gores; Peter Neuhaus; Pierre-Alain Clavien Journal: Hepatology Date: 2011-04 Impact factor: 17.425
Authors: Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater Journal: N Engl J Med Date: 2010-04-08 Impact factor: 91.245
Authors: Matthew J Weiss; David Cosgrove; Joseph M Herman; Neda Rastegar; Ihab Kamel; Timothy M Pawlik Journal: Langenbecks Arch Surg Date: 2014-06-25 Impact factor: 3.445
Authors: Lotte C Franken; Robert J S Coelen; Joris I Erdmann; Joanne Verheij; Marnix P Kop; Thomas M van Gulik; Saffire S Phoa Journal: Quant Imaging Med Surg Date: 2021-11
Authors: Hannes Jansson; Pim B Olthof; Annika Bergquist; Marjolein A P Ligthart; Silvio Nadalin; Roberto I Troisi; Bas Groot Koerkamp; Ruslan Alikhanov; Hauke Lang; Alfredo Guglielmi; Matteo Cescon; William R Jarnagin; Luca Aldrighetti; Thomas M van Gulik; Ernesto Sparrelid Journal: HPB (Oxford) Date: 2021-04-28 Impact factor: 3.647
Authors: Daniele Dondossola; Michele Ghidini; Francesco Grossi; Giorgio Rossi; Diego Foschi Journal: World J Gastroenterol Date: 2020-07-07 Impact factor: 5.742